| Market Cap | 1.46B | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -117.08M | Forward P/E | 8.99 | EPS next Y | - | 50D Avg Chg | -1.00% |
| Sales | 10.23B | PEG | - | EPS past 5Y | -1.14% | 200D Avg Chg | 5.00% |
| Dividend | N/A | Price/Book | 1.58 | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | - | Quick Ratio | 0.52 | Shares Outstanding | 76.50M | 52W Low Chg | 62.00% |
| Insider Own | 2.79% | ROA | 0.97% | Shares Float | 67.66M | Beta | 0.50 |
| Inst Own | 97.28% | ROE | -12.63% | Shares Shorted/Prior | 6.21M/8.39M | Price | 19.14 |
| Gross Margin | 19.18% | Profit Margin | -1.15% | Avg. Volume | 691,143 | Target Price | - |
| Oper. Margin | 3.31% | Earnings Date | Feb 26 | Volume | 563,736 | Change | -0.52% |
Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates in two segments, Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
| JP Morgan | Underweight | Nov 17, 23 |
| Credit Suisse | Neutral | Aug 8, 23 |
| Citigroup | Neutral | May 8, 23 |
| Credit Suisse | Neutral | May 8, 23 |
| UBS | Buy | May 8, 23 |
| Baird | Neutral | May 8, 23 |
| Citigroup | Neutral | Mar 8, 23 |
| Credit Suisse | Neutral | Mar 7, 23 |
| Baird | Neutral | Mar 1, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bernocchi Perry A | EVP, CEO,. Patient D.. EVP, CEO,. Patient Direct | Nov 21 | Sell | 18.7502 | 19,302 | 361,916 | 164,347 | 11/22/23 |
| Leon Jonathan A | SVP, Corporate Treas.. SVP, Corporate Treasurer | Nov 20 | Sell | 18.62 | 5,000 | 93,100 | 98,213 | 11/21/23 |
| Galloway Heath H | EVP,General Counsel.. EVP,General Counsel & CorpSecy | Nov 10 | Sell | 17.57 | 5,500 | 96,635 | 36,479 | 11/13/23 |
| Bruni Alexander J | EVP, CFO EVP, CFO | Nov 10 | Sell | 17.57 | 12,668 | 222,577 | 41,457 | 11/13/23 |
| Pesicka Edward A | President & CEO President & CEO | Jun 15 | Sell | 19.26 | 77,560 | 1,493,806 | 708,373 | 06/20/23 |
| Pesicka Edward A | President & CEO President & CEO | Jun 06 | Sell | 21.21 | 237,854 | 5,044,883 | 1,023,789 | 06/08/23 |
| Henkel Robert J | Director Director | Jul 15 | Buy | 31.76 | 1,000 | 31,760 | 27,000 | 07/15/22 |
| Jochims Jeffrey T | EVP, COO and EVP, COO and | Jun 30 | Sell | 31.31 | 8,000 | 250,480 | 195,956 | 07/05/22 |
| Henkel Robert J | Director Director | Apr 29 | Buy | 35.00 | 2,000 | 70,000 | 26,000 | 05/03/22 |
| Pesicka Edward A | President & CEO President & CEO | Nov 03 | Sell | 41.46 | 56,641 | 2,348,336 | 1,263,785 | 11/04/21 |
| Pace Nicholas J | EVP General Counsel.. EVP General Counsel & CorpSec | Nov 03 | Sell | 43.42 | 49,370 | 2,143,645 | 193,415 | 11/04/21 |
| Lowry Michael Wayne | SVP, Corporate Contr.. SVP, Corporate Controller | Nov 03 | Sell | 43.07 | 32,631 | 1,405,417 | 70,037 | 11/04/21 |
| Leon Jonathan A | SVP, Corporate Treas.. SVP, Corporate Treasurer | May 13 | Sell | 33.24 | 7,500 | 249,300 | 109,707 | 05/13/21 |
| Lowery Christopher M | President, Global Pr.. President, Global Products | May 05 | Option | 0 | 61,882 | 373,269 | 05/05/21 |